Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference29 articles.
1. Metastatic renal cell carcinoma: an invincible enemy?;Greco;Eur Urol,2013
2. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2009
3. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007
4. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial;Sternberg;J Clin Oncol,2010
5. A randomised, double blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update;Sternberg;Eur J Cancer,2013
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09
2. Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review;Kidney Cancer;2021-03-23
3. Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective;Journal of Medical Economics;2021-01-01
4. Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation;Cancer Immunology, Immunotherapy;2020-07-16
5. Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review;PharmacoEconomics;2018-11-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3